Brian Zaugg, MD
Ophthalmology · Salt Lake City, UTNPI 1558660308
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,663 of the $9,081 with a category attached, or 84.4%. 11 manufacturers reported payments, led by Amgen at 34.5% of the total.
Across 26 payments — averaging $349.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- GSK$3K
- Sanofi$2K
- Alcon$620
- Nova Eye, Inc.$234
- Dompe US, Inc.$122
- plus $442 from 5 others
What the payments were for
- Consulting fees$7,66384%
- Food & beverage$1,41816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $3,131 |
| GSK | 1 | $2,600 |
| Sanofi | 1 | $1,932 |
| Alcon | 11 | $620 |
| Nova Eye, Inc. | 1 | $234 |
| Dompe US, Inc. | 1 | $122 |
| Tarsus Pharmaceuticals, Inc. | 1 | $121 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $118 |
| Rxsight Inc | 1 | $113 |
| Glaukos Corporation | 1 | $54 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,081 in reported general payments places this provider in the 85th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 60 | $60,642 |
| Prednisolone Acetate | 434 | $24,695 |
| Cyclosporine | 28 | $12,582 |
| Ketorolac Tromethamine | 116 | $5,127 |
| Fluorometholone | 74 | $4,964 |
| ValacyclovirValacyclovir Hcl | 57 | $4,410 |
| RhopressaNetarsudil Mesylate | 11 | $3,222 |
| MoxifloxacinMoxifloxacin Hcl | 53 | $1,313 |
| Acyclovir | 34 | $1,014 |
| Brimonidine Tartrate | 27 | $827 |
| Latanoprost | 57 | $571 |
| ErythromycinErythromycin Base | 39 | $429 |
| Ofloxacin | 19 | $243 |
| Timolol Maleate | 25 | $170 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 17 | $140 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.